CDMO Leader Fertin Pharma is a global leader in oral and intra-oral delivery systems with end-to-end capabilities from ideation and R&D to manufacturing and regulatory compliance, presenting a strong opportunity to position as a preferred manufacturing partner for pharmaceutical and nutraceutical brands seeking faster time-to-market.

Scale and Patents With over 500 patents and annual production of more than 3.1 billion units, Fertin demonstrates robust intellectual property and scalable manufacturing capacity, making it suitable for large-volume contract manufacturing and complex formulation programs.

Global Footprint Operations across Denmark, Canada, and India plus a diverse tech stack indicate geographic reach and regional capabilities that can support multinational launches, toll manufacturing, and regulatory navigation for global brands.

Strategic Acquisitions Historical interest from major players like Philip Morris and Vectura suggests Fertin’s strategic value in inhaled and oral delivery spaces, signaling potential for partnership discussions, minority investments, or acquisition-aligned collaboration tied to expanding product portfolios.

Financial Health Revenue in the 50 to 100 million range alongside enterprise-grade capabilities positions Fertin as a mid-market CDMO with attractive efficiency, capacity for higher-margin programs, and opportunities to upsell advanced formulations and faster regulatory pathways.